Cooper Companies Inc (COO) FinancialsCOOFinancialCooper Companies Inc

The Cooper Companies, Inc. (COO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Toric and multifocal, accounting for 33.7% of total sales, equivalent to $364.90M. Other significant revenue streams include Sphere, other and Office and surgical procedures. Understanding this composition is critical for investors evaluating how COO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, The Cooper Companies, Inc. maintains a gross margin of 63.59%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.87%, while the net margin is -7.20%. These profitability ratios, combined with a Return on Equity (ROE) of 2.85%, provide a clear picture of how effectively COO converts its operational activities into shareholder value.

In the context of the broader market, COO competes directly with industry leaders such as BAX and RVTY. With a market capitalization of $14.86B, it holds a leading position in the sector. When comparing efficiency, COO's gross margin of 63.59% stands against BAX's 35.41% and RVTY's 57.13%. Such benchmarking helps identify whether The Cooper Companies, Inc. is trading at a premium or discount relative to its financial performance.

Cooper Companies has shown fluctuating revenue, with Q2 2026 revenue at $1.08 billion, but a net loss of $77.9 million. Gross margin has remained relatively stable around 63% in recent quarters, but the decline in net income is concerning.